Pacira reported $3.82M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Astellas Pharma 3.91B 320M Mar/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 128M 9M Mar/2025
Ligand Pharmaceuticals USD 1.15M 286K Jun/2025
Novo Nordisk 4.96B 225M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Perrigo 39.6M 600K Jun/2025
Pfizer USD 654M 0 Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
Teva Pharmaceutical Industries USD 252M 40M Jun/2025
Xeris Pharmaceuticals USD 7.36M 343K Jun/2025
Zoetis USD 53M 1000K Jun/2025